Marshall Wace
SIOX

Marshall Wace’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Marshall Wace’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-47,537
Closed -$103K – 4457
2021
Q3 		$103K Buy
+47,537
New +$103K ﹤0.01% 2886
2021
Q1 		– Sell
-61,383
Closed -$171K – 2982
2020
Q4 		$171K Buy
+61,383
New +$179K ﹤0.01% 1761
2019
Q2 		– Sell
-25,609
Closed -$272K – 1977
2019
Q1 		$272K Buy
+25,609
New +$255K ﹤0.01% 1280

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace's SIOX Position: Q4 2021 in Review

Marshall Wace sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 47,537 shares — an estimated $103K sold.

Marshall Wace first reported a position in SIOX in Q1 2019 and held it in 3 quarters. The position peaked at $272K in Q1 2019. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

  • Marshall Wace reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 47,537 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $103K.
  • Marshall Wace first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2019 and held it in 3 quarters.
  • Marshall Wace's Sio Gene Therapies Inc. Common Stock position peaked at $272K in Q1 2019.
  • 48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.